Tomorrow Bio

Tomorrow Bio has built the one thing that actually differentiates cryonics providers — a vertically integrated medical-response pipeline — rather than brokering the field work out. As Europe's first cryonics company, it operates its own standby team and ambulance to reach members quickly after legal death, performs cryoprotective perfusion in-house, and controls the full chain from stabilization through transport to long-term liquid-nitrogen storage, which directly attacks the biggest determinant of preservation quality: the time and skill between legal death and cooling. The traction is real for a nascent category: as of 2025 it reported around 20 cryopreserved patients, roughly 10 pets, and over 800 members across 45-plus countries, with the company citing a total contract value (largely life-insurance-funded) exceeding €160M — a recurring, pre-committed revenue base most cryonics organizations never assemble. A €5M seed round in May 2025 (co-led by Blast.Club and Truventuro) capitalizes an ambitious but logical next step: US expansion into New York, California, and Florida, planting standby infrastructure in the world's largest cryonics market where incumbents Alcor and the Cryonics Institute are decades old and operationally static. Founder Emil Kendziorra, a physician and former cancer researcher, has professionalized a field long run by hobbyists, and building its own R&D and standby capability positions Tomorrow Bio to compound a quality-and-coverage advantage that is genuinely hard to replicate.